We use cookies on our site to analyze traffic, enhance your experience, and provide you with tailored content.

For more information visit our privacy policy.

November 2023 Sample Clauses

November 2023. No UNTS volume number has yet been determined for this record. The Text(s) reproduced below, if attached, are the authentic texts of the agreement /action attachment as submitted for registration and publication to the Secretariat. For ease of reference they were sequentially paginated. Translations, if attached, are not final and are provided for information only. *Aucun numéro de volume n'a encore été attribué à ce dossier. Les textes disponibles qui sont reproduits ci-dessous sont les textes originaux de l'accord ou de l'action tels que soumis pour enregistrement. Par souci de clarté, leurs pages ont été numérotées. Les traductions qui accompagnent ces textes ne sont pas définitives et sont fournies uniquement à titre d'information.
November 2023. This is an unofficial translation from Finnish. In cases of dispute, the Finnish text is authoritative. 978-952-238-286-3 978-952-238-294-8 (pdf) Xxxxx Oy, 2022 1 SCOPE OF THE AGREEMENT 15 2 BINDING CHARACTER OF THE AGREEMENT AND DUTY OF COMPLIANCE 16 3 PEACE OBLIGATION 16
November 2023. The RL Loan is an unsecured loan on normal commercial terms and constitutes a fully exempted connected transaction, namely financial assistance by a connected person to the Company, under the Listing Rules. Given the current stringent financial position of the Group, the Board considers it is in the best interest of the Company not to proceed with the Subscription (even if Jianlibao Asia agrees to allow the Company to scale down the Subscription) but enter into the Assignment Agreement such that the Company shall be discharged and released from the Rights and Obligations under the Subscription Agreement. With True Choice assuming the obligation to subscribe for Jianlibao Asia’s shares and the set-off of the RL Loan against Subscription Deposit, the Company is relieved from the burden of servicing the RL Loan which would otherwise be extremely difficult in view of the current financial strain of the Company. Further had the Parties not entered into the Assignment Agreement, the Subscription Deposit would have been forfeited under the provision of the Subscription Agreement. True Choice will subscribe for the Adjusted Subscription at the same valuation as the Company subscribed under the Subscription which was based on a valuation of RMB6 billion for 100% of Jianlibao. The Assignment Agreement is the result of friendly negotiation between the Parties on an arm’s length basis with a view to help relieve the Company from further financial burden arising from the default on the Subscription Agreement. The Directors (excluding the independent non-executive directors whose view will be expressed in the circular after considering the opinion of the IFA) believe that the terms of the Assignment Agreement are fair and reasonable, on normal commercial terms after arm’s length negotiations between the Parties and in the interests of the Company and the Shareholders as a whole.
November 2023Final Report A report of outcomes for the funded Activity based on monitoring and data collection methods agreed with between the Parties as per Item E.4 28 July 2024 Financial Acquittal Report Audited Financial Acquittal Report covering the entire Activity period as per Item E.3 31 October 2024 E.1 Performance Reports None Specified
November 2023. Double Red Fosphenytoin sodium (Pro-Epanutin®) ICB Status epilepticus, seizures with head injury,etc. Not recommended for routine use NICE has not issued any guidance. BLACK Fostamatinib Tavlesse® ICB refractory chronic immune thrombocytopenia Not commissioned. No NHS prescribing in primary or secondary care TA759 – January 2022 Hospital Fostamatinib Tavlesse® ICB refractory chronic immune thrombocytopenia Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA835 – October 2022 Double Red Fostemsavir () NHSE HIV infection in combination with other antiretroviral drugs Not recommended for routine use NICE has not issued any guidance. Hospital FreeStyle Libre BGS device (sensors are "Advice"") (FreeStyle Libre) ICB Blood Glucose Monitoring in diabetes as per NHSE criteria March 2019 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance ADVICE FreeStyle Libre BGS sensors (BGS device is "Red") (FreeStyle Libre) ICB Blood Glucose Monitoring in diabetes as per NHSE criteria March 2019 Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant/Specialist responsible for the first script. NICE has not issued any guidance. Hospital Fremanezumab Ajovy® ICB preventing migraine Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA764 – February 2022 BLACK Fulvestrant (Faslodex®) NHSE Treatment of locally advanced or metastatic breast cancer - as per NICE TA 503 Not commissioned. No NHS prescribing in primary or secondary care TA503 - Jan 18 Hospital Fumaric acid ester (Fumaderm (unlicensed product)) ICB Severe psoriasis - specialist use only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Gabapentin (Neurontin®) ICB Neuropathic pain Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. AMB Galantamine (Reminyl®) ICB Mild to moderate Alzheimer's dementia - as per NICE TA 217 Prescribe the drug and perform a basic level of monitoring, e.g. a standard annual review TA217 - Mar 11 B...
November 2023. Cancer Institute – Xxxxxx xxx Xxxxxxxxxxx hospital, I work for and amidst patients, researchers and clinicians. As a result, I use and interpret the legislation and legal theory of data protection in my daily work, and vice versa. The case studies in this thesis reflect daily practice in health care and secondary health research. My research strategy has consisted of four steps.17 First, I identified the field of re- search, i.e. data protection in health care and health research. Secondly, I collected sources. I collected documents on the letter of the law, publications and academic research carried out in previous studies. Thirdly, I analyzed the sources and, finally, I interpreted the sources. Often, the four steps of the research strategy took place paral- lel to each other, whilst I observed converging and diverging developments as regards both European and national law, and the viewpoints of legal scholars and practitioners in this field. I started this thesis at the xxxx of the COVID-19 pandemic when the urgent need for data sharing for health and research became all the more apparent.
November 2023. Skills First Aboriginal Access fee Individuals who have self-identified as Aboriginal or Xxxxxx Xxxxxx Islander descent and meet all the eligibility requirements to access a government funded training place. Under the Indigenous Completions Initiative, for enrolments in a course at any level the RTO must charge the concession fee to individuals who self- identify as being Aboriginal or Xxxxxx Xxxxxx Islander descent. The RTO must retain a copy of the enrolment form on which the individual self- identified as indigenous. • ‘Client tuition fee’ = ‘0’ (zero) - indicating you have charged $0 tuition fees • ‘Fee concession/exemption type identifier’ second character (fee waiver character) = ‘F’ – indicating you’ve 2024 reporting advice for the new Skills First Aboriginal Access fee – 21 December 2023
November 2023. Except as otherwise revised, modified or supplemented in this Article VIII, ATTACHMENT D – HHS UNIFORM TERMS AND CONDITIONS – GRANT, V3.3, NOVEMBER 2023, controls.
November 2023. The content of the Agreement is referable to a shareholders' agreement pursuant to Article 122, paragraph 5, letter d-bis), of the TUF. In the Agreement is conferred the entire shareholding held at the Effective Date by Steris UK, equal to 1,877,607 shares of Servizi Italia, representing 5.903% of its share capital and voting rights. The Shareholders' Agreement was filed with the Xxxxxx Register of Companies on 13 November 2023 and will be sent in its full version to Consob within the terms required by the applicable law.
November 2023. A. Whereas the land subject to this Agreement (the “Agreement Area”) is within Hənʎəmdᶻi Məkola/Yorke Island Conservancy, and whereas Hənʎəmdᶻi Məkola/Yorke Island Conservancy is within the traditional territories of the K’omoks First Nation, We Wai Kai First Nation, Xxx Xxx Xxx First Nation & Xwemalhkwu First Nation whose relationship with the land continues to this day.